- Trial phase
- Approved
- Time to market
- Already approved and commercially available since mid-2023.
- Why 4/10
- Abrysvo is already approved and commercialized with no pending regulatory decision (PDUFA or pivotal readout) in the next 12 months. It is a meaningful product but represents a small fraction of Pfizer's $62-64 billion annual revenue. The next catalysts are quarterly sales reports, which are not binary events. Per the rubric, an approved drug with no upcoming binary scores 3-5, and 4 reflects its moderate commercial importance within a diversified giant.
Abrysvo has no upcoming PDUFA dates or pivotal readouts; it is an approved, commercial product. Watch Pfizer's quarterly earnings reports for Abrysvo sales trends, particularly during the fall RSV season (September-January). The key competitive dynamic to monitor is whether Abrysvo can gain market share from GSK's Arexvy following its broader adult label (18-59 at-risk) and whether the GBS warning materially impacts uptake.
Price Chart
Executive Summary
Abrysvo is Pfizer's FDA-approved respiratory syncytial virus (RSV) vaccine, launched in mid-2023. It holds a unique position as the only RSV vaccine approved for pregnant women to protect newborns and the only one approved for adults as young as 18 (at-risk). However, it faces stiff competition from GSK's Arexvy, which dominates the market, and Moderna's mRESVIA. Sales have declined from $890 million in its first year to $755 million in 2024, and a GBS warning was added to the label in January 2025. For Pfizer, a $62-64 billion revenue company, Abrysvo is a meaningful but not dominant product, and no upcoming binary regulatory catalysts are scheduled.
How It Works
Abrysvo is a vaccine that trains the immune system to recognize and fight respiratory syncytial virus (RSV). It contains a purified version of a key RSV surface protein (the prefusion F protein) from two major RSV subtypes (A and B). When injected, the body produces antibodies against this protein, blocking the virus from entering cells. In pregnant women, these antibodies cross the placenta and protect the newborn for the first six months of life.
Trial Status
Abrysvo was approved by the FDA in May 2023 for adults 60 and older, in August 2023 for pregnant individuals to protect infants, and in October 2024 for adults aged 18-59 at increased risk of severe RSV. The pivotal Phase 3 MATISSE trial (NCT04424316) enrolled over 7,000 pregnant individuals and demonstrated efficacy against RSV-associated lower respiratory tract disease in infants. Post-marketing observational studies are ongoing, including a real-world effectiveness study with the University of Pittsburgh.
The Two-Sided Case
Upcoming Catalysts
- No upcoming PDUFA dates or pivotal readouts identified for Abrysvo; it is an approved, marketed product. Future catalysts are limited to quarterly sales reports and potential label expansions (e.g., pediatric use, which is under investigation per EMA requirements).
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PFIZER INC 8-K PFE ·Originating report